Cybin Initiates Dosing Of Final Cohort Of Its Phase 2 Trial Of CYB003 In Major Depressive Disorder
Portfolio Pulse from Happy Mohamed
Cybin Inc. has initiated dosing in the final cohort of its Phase 2 study evaluating CYB003, a potential treatment for major depressive disorder. The first five cohorts have completed dosing with no serious adverse events. The company expects to report Phase 2 efficacy topline data later this year and prepare for data submission to the FDA for pivotal studies. Completion of CYB003 dosing in MDD cohorts is expected in Q3 2023, with topline efficacy data readout expected in Q3/Q4 2023.
August 04, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin Inc. has initiated the final phase of its Phase 2 study for CYB003, a potential treatment for major depressive disorder. The company expects to report topline efficacy data later this year, which could impact the stock positively if the results are favorable.
The initiation of the final phase of the Phase 2 study for CYB003 is a significant milestone for Cybin Inc. If the results are favorable and the company can report positive topline efficacy data later this year, this could have a positive impact on the company's stock. However, the final impact will depend on the actual results and the market's reaction to them.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100